HIV / AIDS in the News

HIV-Infected Patient Refused Care In Armenia - Radio Free Europe / Radio Liberty

 

Affordability and supply remain critical to the success of long-lasting HIV drug - News-Medical.Net

 

High-level panel on a resilient and fit-for-purpose UNAIDS Joint Programme in the context of the sustainability of the HIV response - UNAIDS

 

Tennessee replaced its federal HIV funding with state money. Public health experts say the change is causing damage. - WPLN

 

Long-Acting Injectable HIV Therapy: Addressing Adherence Challenges - Contagionlive.com

 

Gilead, MRK Report Data From Investigational Combination Study for HIV - Zacks Investment Research

 

Seeing More Than HIV: Why “Patient Reported Outcomes” Matter - MD Magazine

 

Multiple Paths to HIV Prevention: The Power of Choice - Metro Weekly

 

Protect Yourself from the Flu: Important Info for People With HIV - HIV.gov

 

Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks - Yahoo Finance

 

Analyzing Knowledge Status and HIV Linkage to Care: Insights From America’s HIV Epidemic Analysis Dashboard (AHEAD) National Database - Cureus

 

Success of long-lasting HIV drug hinges on pricing - SciDev.Net

 

UNAIDS calls for global solidarity to strengthen Madagascar’s HIV response to end AIDS as a public health threat - UNAIDS

 

US government proposes birth control, HIV preventive service protections - Fierce healthcare

 

Gilead and Merck tout first weekly oral HIV treatment - The Pharma Letter

 

Program Assistant, Re-Envisioning Excellence and Accessibility in Clinic-based HIV Services (REACH 95) project - Kyiv Post

 

HIV cases rising in Alberta, sparking need for broad outreach, experts say - Yahoo News Canada

 

Groups With Highest Unmet PrEP Needs Emerge in Analysis - Medscape

 

Torque teno virus: a potential marker of immune reconstitution in youths with vertically acquired HIV - Nature.com

 

Gilead, MSD say HIV combo could be weekly, oral HIV drug - pharmaphorum

 

Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks, setting stage for pivotal program - Fierce Biotech

 

Do the comms around HIV need an urgent rethink? - PR Week

 

Peru approves groundbreaking law to extend health coverage for migrants with HIV and TB - UNAIDS

 

HIV cases rising in Alberta, sparking need for broad outreach, experts say - CBC.ca

 

HIV infections no longer falling; On the rise among young men - NL Times

 

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48 - BioSpace

 

Successful Biological Treatment of a Patient With Psoriasis and HIV - Cureus

 

New Strategies to Extend the HIV Treatment Cascade for CVD Prevention - Infectious Disease Special Edition

 

Sweden exceeds UNAIDS HIV goals but faces new challenges - News-Medical.Net

 

Fighting the stigma: A Detroit HIV survivor shares his story to help others with virus - Detroit News